AOD-9604: The hGH 176-191 Fragment and a Literature Dominated by Detection

Design rationale

Full-length growth hormone signals through the growth hormone receptor and drives IGF-1 production, which is responsible for its anabolic and growth effects. It also affects insulin sensitivity. The C-terminal fragment was selected on the premise that the lipolytic activity resides in that region and does not require the receptor interactions that produce the rest of the hormone's effects.

The practical consequence of that design, if the premise holds, is a compound that does not raise IGF-1. That is the property the anti-doping literature repeatedly tests for, and it is the clearest experimental signal available about the compound.

What the detection literature establishes

Orlovius et al. (Drug Test Anal, 2013) report that AOD-9604 does not interfere with the WADA hGH isoform immunoassay. Cox et al. (Drug Test Anal, 2015) characterise its detection and in vitro metabolism. Thevis and Schänzer have published repeatedly on detecting this class of compound in doping control.

This body of work is genuinely useful for a different reason than intended: it is the most rigorous analytical characterisation the compound has received. Metabolic fate and assay behaviour are better described than efficacy.

The clinical programme

Wilding's 2004 review in Current Opinion in Investigational Drugs covers AOD-9604 as a metabolic candidate, and Halford's 2006 review places it among obesity drugs then in clinical development. The programme did not proceed to approval.

Two 2026 reviews, in Sports Medicine and in the Journal of the AAOS Global Research and Reviews, group it with other unapproved peptide therapies. Neither adds primary efficacy data.

A fair reading is that the separation-of-function hypothesis was tested and the compound did not clear the bar for an obesity indication. Absence of approval is not proof of absence of effect, but there is no substantial positive literature to weigh against it either.